Figure 2.

Regression on computerized tomographic scan of the abdomen of pancreatic cancer in a patient with KRAS and CDKN2A/B alterations managed with trametinib and palbocicib

This is an 86-year-old woman (study ID: 2; Figure 1) with metastatic adenocarcinoma of pancreas. Patient was initially treated with gemcitabine and albumin-bound paclitaxel. Upon progression, under the I-PREDICT study, patient was started on trametinib (for KRAS Q61H) and palbociclib (for CDKN2A/B loss). Imaging showed decrease in pancreatic mass (29% reduction) (measurements in upper right hand corner); images with largest diameter of tumor selected in each case.